| Doxorubicin |
EU/1/12/769/001EU/1/00/141/001 |
Myocet, Powder, dispersion and solvent for concentrate for dispersion for infusion, 50, mg, Pack: 2 |
Cephalon Europe, Франция |
GP-Pharma Poligon Industrial Els Vinyets – Els Fogars, Sector 2, Carretera Comarcal C244, km22 08777 Sant Quinti de Mediona (Barcelona) Spain; Teva Operations Poland Sp. z o.o., ul. Mogilska 80, 31-546 |
1865.16 |
373.03 |
2238.19 |
4% |
10 |
1875.16 |
375.03 |
2250.19 |
16% |
25 |
1900.16 |
380.03 |
2280.19 |
|
КЦРР-1702/27.11.2012 |
12.12.2012 |
12.12.2012 |
Неактивен |
3463 |
| Technetium [99mTc] tetrofosmin |
II-15004/24.11.2006 |
Myoview, Powder for solution for injection, 230, mcg, Pack: 5 vial (kit for radiopharmaceutical preparation) |
GE Healthcare AS, Норвегия |
GE Healthcare AS, Норвегия |
1093.31 |
218.66 |
1311.97 |
4% |
10 |
1103.31 |
220.66 |
1323.97 |
16% |
25 |
1128.31 |
225.66 |
1353.97 |
НСР-20918/27.02.2020 промяна на обстоятелства |
КЦ-823/15.04.2009 |
30.04.2009 |
02.04.2020 |
Активен |
711 |
| Technetium [99mTc] tetrofosmin |
II-15004/24.11.2006 |
Myoview, Powder for solution for injection, 230, mcg, Pack: 5 vial (kit for radiopharmaceutical preparation) |
GE Healthcare Ltd, Обединено Кралство |
GE Healthcare Limited |
1093.31 |
218.66 |
1311.97 |
4% |
10 |
1103.31 |
220.66 |
1323.97 |
16% |
25 |
1128.31 |
225.66 |
1353.97 |
|
КЦ-823/15.04.2009 |
30.04.2009 |
30.04.2009 |
Неактивен |
711 |
| Technetium [99mTc] tetrofosmin |
II-15004/24.11.2006 |
Myoview, Powder for solution for injection, 230, mcg, Pack: 5 vial (kit for radiopharmaceutical preparation) |
GE Healthcare Ltd, Обединено Кралство |
GE Healthcare Limited |
1093.31 |
218.66 |
1311.97 |
4% |
10 |
1103.31 |
220.66 |
1323.97 |
16% |
25 |
1128.31 |
225.66 |
1353.97 |
|
КЦ-823/15.04.2009 |
30.04.2009 |
30.04.2009 |
Неактивен |
711 |
| Alglucosidase alfa |
EU/1/06/333/001 |
Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., UK; Genzyme Ireland Ltd., Ирландия |
790.68 |
158.14 |
948.82 |
4% |
10 |
800.68 |
160.14 |
960.82 |
16% |
25 |
825.68 |
165.14 |
990.82 |
Промяна на обстоятелства НСР-19627/21.08.2019 |
НСР-8521/16.03.2016; НСР-10987/24.11.2016; НСР-14190/13.10.2017; НСР-15921/15.06.2018 |
30.06.2018 |
02.10.2019 |
Активен |
3264 |
| Alglucosidase alfa |
EU/1/06/333/001 |
Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., UK; Genzyme Ireland Ltd., Ирландия |
790.68 |
158.14 |
948.82 |
4% |
10 |
800.68 |
160.14 |
960.82 |
16% |
25 |
825.68 |
165.14 |
990.82 |
Промяна на обстоятелства НСР-19627/21.08.2019 |
НСР-8521/16.03.2016; НСР-10987/24.11.2016; НСР-14190/13.10.2017; НСР-15921/15.06.2018 |
30.06.2018 |
02.10.2019 |
Неактивен |
3264 |
| Alglucosidase alfa |
EU/1/06/333/001 |
Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., UK |
790.68 |
158.14 |
948.82 |
4% |
10 |
800.68 |
160.14 |
960.82 |
16% |
25 |
825.68 |
165.14 |
990.82 |
|
НСР-8521/16.03.2016; НСР-10987/24.11.2016; НСР-14190/13.10.2017; НСР-15921/15.06.2018 |
30.06.2018 |
02.07.2018 |
Неактивен |
3264 |
| Alglucosidase alfa |
EU/1/06/333/001 |
Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., UK |
807.91 |
161.58 |
969.49 |
4% |
10 |
817.91 |
163.58 |
981.49 |
16% |
25 |
842.91 |
168.58 |
1011.49 |
|
НСР-8521/16.03.2016; НСР-10987/24.11.2016; НСР-14190/13.10.2017 |
28.10.2017 |
02.11.2017 |
Неактивен |
3264 |
| Alglucosidase alfa |
EU/1/06/333/001 |
Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., UK |
828.06 |
165.61 |
993.67 |
4% |
10 |
838.06 |
167.61 |
1005.67 |
16% |
25 |
863.06 |
172.61 |
1035.67 |
|
НСР-8521/16.03.2016; НСР-10987/24.11.2016 |
02.01.2017 |
02.01.2017 |
Неактивен |
3264 |
| Alglucosidase alfa |
EU/1/06/333/001 |
Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., UK |
832.99 |
166.6 |
999.59 |
4% |
10 |
842.99 |
168.6 |
1011.59 |
16% |
25 |
867.99 |
173.6 |
1041.59 |
|
НСР-8521/16.03.2016 |
31.03.2016 |
31.03.2016 |
Неактивен |
3264 |
| Alglucosidase alfa |
EU/1/06/333/001 |
Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., UK |
832.99 |
166.6 |
999.59 |
4% |
10 |
842.99 |
168.6 |
1011.59 |
16% |
25 |
867.99 |
173.6 |
1041.59 |
|
НСР-8521/16.03.2016 |
31.03.2016 |
31.03.2016 |
Неактивен |
3264 |
| Alglucosidase alfa |
EU/1/06/333/001 |
Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., UK |
838.58 |
167.72 |
1006.3 |
4% |
10 |
848.58 |
169.72 |
1018.3 |
16% |
25 |
873.58 |
174.72 |
1048.3 |
|
НСР-6598/01.07.2015 |
17.07.2015 |
17.07.2015 |
Неактивен |
3264 |
| Alglucosidase alfa |
EU/1/06/333/001 |
Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., UK |
844.06 |
168.81 |
1012.87 |
4% |
10 |
854.06 |
170.81 |
1024.87 |
16% |
25 |
879.06 |
175.81 |
1054.87 |
|
НСР-4936/22.10.2014 |
06.11.2014 |
06.11.2014 |
Неактивен |
3264 |
| Alglucosidase alfa |
EU/1/06/333/001 |
Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd. UK |
862.15 |
172.43 |
1034.58 |
4% |
10 |
872.15 |
174.43 |
1046.58 |
16% |
25 |
897.15 |
179.43 |
1076.58 |
корекц. Решение НСР-3158/26.03.2014 |
НСР-2771/17.02.2014 |
06.03.2014 |
06.03.2014 |
Неактивен |
3264 |
| Alglucosidase alfa |
EU/1/06/333/001-003 |
Myozyme, Powder for concentrate for solution for infusion, 50, mg, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd. UK |
916.27 |
183.25 |
1099.52 |
4% |
10 |
926.27 |
185.25 |
1111.52 |
16% |
25 |
951.27 |
190.25 |
1141.52 |
|
HCР-18/31.05.2013 |
02.06.2013 |
02.06.2013 |
Неактивен |
3264 |
| Galsulfase |
EU/1/05/324/001 |
Naglazyme, Concentrate for solution for infusion, 1mg/ml, 5 ml, Pack: 1 |
BioMarin Europe Limited, Обединено Кралство |
Catalent UK Packaging Ltd, Великобритания |
2543.38 |
508.68 |
3052.06 |
4% |
10 |
2553.38 |
510.68 |
3064.06 |
16% |
25 |
2578.38 |
515.68 |
3094.06 |
корекционно решение НСР-6891/30.07.2015; цената е вписана в регистъра на пределните цени с решение НСР-7947/08.02.2016 г.(в сила от 02.03.2016) |
НСР-6483/18.06.2015 |
04.07.2015 |
04.07.2015 |
Заличен |
3285 |
| Galsulfase |
EU/1/05/324/001 |
Naglazyme, Concentrate for solution for infusion, 1mg/ml, 5 ml, Pack: 1 |
BioMarin Europe Limited, Обединено Кралство |
Catalent UK Packaging Ltd, Великобритания |
2630.06 |
526.01 |
3156.07 |
4% |
10 |
2640.06 |
528.01 |
3168.07 |
16% |
25 |
2665.06 |
533.01 |
3198.07 |
|
НСР-4918/22.10.2014 |
06.11.2014 |
06.11.2014 |
Неактивен |
3285 |
| Galsulfase |
EU/1/05/324/001 |
Naglazyme, Concentrate for solution for infusion, 1mg/ml, 5 ml, Pack: 1 |
BioMarin Europe Limited, Обединено Кралство |
Catalent UK Packaging Ltd, Великобритания |
2684.87 |
536.97 |
3221.84 |
4% |
10 |
2694.87 |
538.97 |
3233.84 |
16% |
25 |
2719.87 |
543.97 |
3263.84 |
|
НСР-1027/23.08.2013 |
09.09.2013 |
09.09.2013 |
Неактивен |
3285 |
| Diclofenac |
20030384 |
Naklofen, Solution for injection, 75 mg/3 ml, mg, Pack: 5 |
KRKA, d.d., Словения |
KRKA, d.d. Novo Mesto, Slovenia |
1.9 |
0.38 |
2.28 |
7% |
0.13 |
2.03 |
0.41 |
2.44 |
20% |
0.38 |
2.41 |
0.48 |
2.89 |
промяна на обстоятелства НСР-10708/21.10.2016 |
НСР-558/23.07.2013 |
04.09.2013 |
02.12.2016 |
Активен |
2055 |
| Diclofenac |
20030384 |
Naklofen, Solution for injection, 75 mg/3 ml, mg, Pack: 5 |
KRKA, d.d., Словения |
KRKA, d.d. Novo Mesto, Slovenia |
1.9 |
0.38 |
2.28 |
7% |
0.13 |
2.03 |
0.41 |
2.44 |
20% |
0.38 |
2.41 |
0.48 |
2.89 |
промяна на обстоятелства НСР-10708/21.10.2016 |
НСР-558/23.07.2013 |
04.09.2013 |
02.12.2016 |
Неактивен |
2055 |
| Diclofenac |
II-3430/ 11,11,2008 |
Naklofen, Solution for injection, 75 mg/3 ml, mg, Pack: 5 |
KRKA, d.d., Словения |
KRKA, d.d. Novo Mesto, Slovenia |
1.9 |
0.38 |
2.28 |
7% |
0.13 |
2.03 |
0.41 |
2.44 |
20% |
0.38 |
2.41 |
0.48 |
2.89 |
|
НСР-558/23.07.2013 |
04.09.2013 |
04.09.2013 |
Неактивен |
2055 |
| Diclofenac |
II-3430/ 11,11,2008 |
Naklofen, Solution for injection, 75 mg/3 ml, mg, Pack: 5 |
KRKA, d.d., Словения |
KRKA, d.d. Novo Mesto, Slovenia |
2.46 |
0.49 |
2.95 |
7% |
0.17 |
2.63 |
0.53 |
3.16 |
20% |
0.49 |
3.12 |
0.62 |
3.74 |
корекц решение № КЦРР-541/04.05.2012 |
КЦРР-510/19.04.2012 |
06.05.2012 |
06.05.2012 |
Неактивен |
2055 |
| Diclofenac |
II-3430/11,11,2008 |
Naklofen, Solution for injection, 75 mg/3 ml, mg, Pack: 5 |
KRKA, d.d., Словения |
KRKA, d.d. Novo Mesto, Slovenia |
2.72 |
0.54 |
3.26 |
9% |
0.24 |
2.96 |
0.59 |
3.55 |
22% |
0.6 |
3.56 |
0.71 |
4.27 |
|
КЦ-412/07.01.2009 |
02.02.2009 |
02.02.2009 |
Неактивен |
2055 |
| Diclofenac |
II-3578/2 6.11.2008 |
Naklofen, Gastro resistant tablet, 50, mg, Pack: 20 |
KRKA, d.d., Словения |
KRKA. d.d. Novo Mesto. Slovenia |
1.62 |
0.32 |
1.94 |
7% |
0.11 |
1.73 |
0.35 |
2.08 |
20% |
0.32 |
2.05 |
0.41 |
2.46 |
Цената е вписана в регистъра на пределните цени с решение НСР-2683/03.02.2014 |
КЦРР-499/19.04.2012 |
06.05.2012 |
06.05.2012 |
Заличен |
1193 |
| Diclofenac |
II-3578/26,11,2008 |
Naklofen, Gastro resistant tablet, 50, mg, Pack: 20 |
KRKA, d.d., Словения |
KRKA, d.d. Novo Mesto, Slovenia |
1.7 |
0.34 |
2.04 |
9% |
0.15 |
1.85 |
0.37 |
2.22 |
22% |
0.37 |
2.22 |
0.44 |
2.66 |
|
КЦ-412/07.01.2009 |
02.02.2009 |
02.02.2009 |
Неактивен |
1193 |